Clinical comprehensive evaluation of 6 GLP-1RAs for treating type 2 diabetes mellitus
OBJECTIVE To collect relevant evidence of evidence-based medicine of GLP-1RAs for treating type 2 diabetes mellitus(T2DM)to obtain intuitive results of comprehensive clinical evaluations and provide evidence-based medical supports and references for the introduction and rational use of GLP-1RAs at healthcare institutions.METHODS A comprehensive clinical evaluation system of drugs with GLP-1RAs for treating T2DM was constructed through literature researching and expert consult-ing.Six GLP-1RAs were objectively evaluated with references to evidence-based medical evidence and studies of six dimensions of safety,efficacy,economy,innovation,appropriateness and accessibility of GLP-1RAs for treating T2DM in the relevant drug inserts,drug registrations,English databases(PubMed,Embase&Cochrane Library)and Chinese database(China National Knowledge Infrastructure,CNKI).RESULTS The final outcome scores were,in a descending order,semaglutide(85.10),dulaglutide(79.25),liraglutide(76.85),polyethylene glycol loxenatide(70.25),lixisenatide(65.00)and exenatide(63.50).CONCLUSION Based upon the evaluation results,when GLP-1RAs are introduced and rationally used clinically at healthcare organizations,Top three of semaglutide,dulaglutide and liraglutide are recommended drugs.
glucagon-like peptide-1 receptor agonisthospital health technology assessmenthealthcare organization drug selectiontype 2 diabetes mellituscomprehensive clinical evaluation of drugs
NETL
NSTL
万方数据
